UK markets closed

Arbutus Biopharma Corporation (ABUS)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
3.2900+0.0100 (+0.30%)
At close: 04:00PM EDT
3.3000 +0.01 (+0.30%)
After hours: 06:48PM EDT
Show:
Income statement
Balance sheet
Annual

Cash flow

All numbers in thousands
Breakdown
ttm
31/12/2023
31/12/2022
31/12/2021
31/12/2020
31/12/2019
Cash flows from operating activities
Net income
-74,385
-72,849
-69,456
-76,247
-63,745
-
Depreciation & amortisation
1,425
1,404
1,427
1,753
1,978
-
Deferred income taxes
-
-
-
-
0
-12,661
Stock-based compensation
9,184
9,301
7,182
6,424
6,161
-
Change in working capital
-8,758
-18,233
29,243
925
431
-
Accounts receivable
525
-424
-453
413
-108
-
Accounts payable
-
-
5,216
1,911
1,666
-2,410
Other working capital
-78,916
-86,944
-35,868
-68,341
-51,670
-
Other non-cash items
-3,012
-3,343
-3,698
-1,386
1,035
-
Net cash provided by operating activities
-77,930
-85,936
-35,356
-67,532
-51,441
-
Cash flows from investing activities
Investments in property, plant and equipment
-986
-1,008
-512
-809
-229
-
Acquisitions, net
-
-
-
-
-2,500
0
Purchases of investments
-85,701
-80,509
-130,430
-82,219
-85,578
-
Sales/maturities of investments
-
132,270
56,000
70,350
73,398
-
Other investing activities
-
-
-
-
-12,180
28,916
Net cash used for investing activities
45,789
50,773
-74,942
-12,678
-14,909
-
Cash flows from financing activities
Debt repayment
-
-
-
-
-
0
Common stock issued
31,755
29,852
20,324
134,665
86,297
-
Other financing activities
-
-
-
-
-
18,549
Net cash used provided by (used for) financing activities
34,660
30,647
31,814
137,236
86,746
-
Net change in cash
2,527
-4,491
-78,506
57,031
20,452
-
Cash at beginning of period
40,574
30,776
109,282
52,251
31,799
-
Cash at end of period
43,093
26,285
30,776
109,282
52,251
-
Free cash flow
Operating cash flow
-77,930
-85,936
-35,356
-67,532
-51,441
-
Capital expenditure
-986
-1,008
-512
-809
-229
-
Free cash flow
-78,916
-86,944
-35,868
-68,341
-51,670
-